87. Kami| Link| Bookmark|
May 19, 2023 7:45:28 AM
Top Contributor (300+ Posts, 100+ Likes)
Out of topic, help me with my query. Since giving yearly result is compulsory and that is too before 60 days from March, company which are listing right now ( remus, krischa, Vasa, and etc) are they gonna give result before May? That's means before their listing also?
As per the rule (don't remember SEBI or Companies Act), any company which is listed or in the process of listing has to post it's quarterly result/yearly result (whichever is applicable). A good example was Vital Chemtech who listed on 14th November and gave result on 14th November(last date). So Remus, Krishca and Auro will post. In process of listing also include Vasa, Crayon, etc., but I am not sure whether they would post result or not.
One more example is Cargotrans who got listed in October and then gave intimation that quarterly result is not applicable and then they realised this rule and posted quarterly result on 22nd/23rd Nov which was late but they did post.
Anything can happen in SME but valuations are not justified. May be it can list 200+ but gradually it will come down to IPO price. It will not go negative, I guess.
@Gaurav DD dimer sir.......what is view of chaman matalic can cross listing price befor Q4 result
79. YBPK| Link| Bookmark|
May 18, 2023 8:31:42 PM
Top Contributor (200+ Posts, 600+ Likes)
Company is in the business of marketing & distribution of finished formulations with products sourced from either group companies or other vendors Pre IPO fund raising list contains name of Rekha Gunavanth kumar, Prashant Mishra, Hemant Iswarlal Modi, Ten Eighty Investments etc. Pre IPO fund raising was done @ Rs 500 per share in on 30=dec-22 and 5 month later, IPO is priced at Rs 1229. In a way, it is a positive sign as the promoters could have given themselves bonus for free, but instead have bought cash in the company. Indicative receivables as on 31-mar-24 are Rs 1315 lacs and with a DSO of 2.5 months, the indicative turnover for 23-24 is around Rs 6312 lacs PBT to cash flow from operation conversion has been consistent and good for the last 4 years, inventory and receivables have not increased despite increase in sales Exports constitute more than 90% of sales with top 10 customers contributing more than 70% of the sales Company has subscribed to 0% fully convertible debentures worth Rs 20.53 cr of Ratnatris Pharma which practically makes Ratnatris its subsidiary. Ratnatris has received Income Tax demand notice of Rs 20 cr Ratnatris made a loss of Rs 8.28 cr on turnover of Rs 80.37 cr for 21-22. If these were to be consolidated with Remus financials, profitability and networth of Remus would drop drastically. Salary and perquisites of 4 family directors amounts to Rs 4.15 Cr per year out of annualized employee cost of Rs 5.41 cr for 22-23 Company’s focus markets appear to be Latin American countries and a sprinkling of SEA and Central European countries. Company claims to have 295 products registered in 13 countries with another 134 products under process for registration. Bolivia, Dominican Republic, Guatemala and Ecuador have 302 of the 429 product registrations
Remus is also subscribed about 50x. Beyond any expectations. Krishca also subscribed heavily. Allotment in both are subject to lottery. Lottery is always Lottery. Between 50x or 500x.Any lucky subscriber can win a lottery. No regret. This may be you or me !!!
Looking present subscription figures and on going SME Krishca, it is difficult to cross 30x. Reports on pricing by members is also not looking favorable for good subscription figures. Other SME are also there. GMP not so attractive. In such circumstances even 30x looks very difficult. But it's investors, difficult to predict their mood. My thinking.